Patient Experience

Patient Experience

Destiny Gastric04 DS8201-A-U306

A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen
Description:
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

Fortitude

A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
Description:
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

ZWI-ZW25 -301

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Description:
Study Phase: Phase 3
Principal Investigator: Maeve Lowery
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry